Cargando…

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

OBJECTIVE: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Cheolmin, Pae, Chi-Un, Kwak, Kyung Phil, Jeon, Sang Won, Jeong, Hyun-Ghang, Kim, Jong-Woo, Lee, Youn Jung, Patkar, Ashwin A., Han, Changsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077065/ https://www.ncbi.nlm.nih.gov/pubmed/33888653 http://dx.doi.org/10.9758/cpn.2021.19.2.243

Ejemplares similares

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
por: Han, Changsu, et al.
Publicado: (2015)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises
por: Pae, Chi-Un, et al.
Publicado: (2014)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study
por: Jeon, Sang Won, et al.
Publicado: (2017)

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
por: Cocchi, Enrico, et al.
Publicado: (2016)

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
por: Wang, Sheng-Min, et al.
Publicado: (2018)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples
por: Porcelli, Stefano, et al.
Publicado: (2016)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009)

A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders
por: Jeon, Sang Won, et al.
Publicado: (2017)

Pain and Depression: A Neurobiological Perspective of Their Relationship
por: Han, Changsu, et al.
Publicado: (2015)

The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
por: Porcelli, Stefano, et al.
Publicado: (2015)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

Examining Stress and Residual Symptoms in Remitted and Partially Remitted Depression Using a Wearable Electrodermal Activity Device: A Pilot Study
Publicado: (2022)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Retrospective Case Series of Aripiprazole Augmentation in Pervasive Developmental Disorders
por: Kim, Yeni, et al.
Publicado: (2010)

Plasminogen Activator Inhibitor-1: Potential Inflammatory Marker in Late-life Depression
por: Lee, Seung-Hoon, et al.
Publicado: (2023)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8905hjburi6ncdcjihicuq3g5v